<DOC>
	<DOC>NCT01660802</DOC>
	<brief_summary>This study will assess the safety and efficacy of 700 Î¼g dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in patients with macular edema in a 6 month double-blind period versus sham followed by a 2 month open label period.</brief_summary>
	<brief_title>Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Presence of macular edema defined as macular thickening involving the center of the macula due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) History of glaucoma, ocular hypertension or optic nerve head change Any active bacterial, viral, parasitic, or fungal infections in either eye Eye surgery, including cataract surgery, and/or laser of any type in the study eye within 3 months prior to study start History of use of intravitreal steroids or any intravitreal injectable drug in the study eye within 3 months prior to study start Use of oral, intravenous, intramuscular, epidural, rectal, or extensive dermal steroids within 1 month prior to study start Use of immunosuppressants, immunomodulators, antimetabolites, and/or alkylating agents within 3 months prior to study start Use of topical ophthalmic corticosticosteroids within 2 weeks of study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>